Inovio’s DNA Vaccine Generates Robust Responses Against COVID-19 Variants in Study

Shares of Inovio were climbing in early trading this morning after the company announced its DNA vaccine candidate for COVID-19 induced a robust T-cell response against multiple variants of the SARS-CoV-2 virus.